UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~June~~March 3031, ~~2006~~2008

ORor

o	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: _______ to ________.

Commission File No. 1-12451

NEW YORK HEALTH CARE, INC.

(Exact name of registrant as specified in its charter)

New York	11-2636089
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

1850 McDonald Avenue, Brooklyn, New York	11223
(Address of principal executive offices)	(Zip Code)

Issuer's telephone number, including area code: (~~212~~718) ~~679~~378-~~7778~~6700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o࿠ Accelerated filer o࿠ Non-accelerated filer ࿠ (Do not check if a smaller reporting company) Smaller reporting company x

~~APPLICABLE~~Indicate ~~ONLY~~by TOcheck ~~ISSUERS~~mark ~~INVOLVED~~whether INthe ~~BANKRUPTCY~~registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

~~PROCEEDINGS~~Yes o ~~DURING THE PRECEDING FIVE YEARS~~No x

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 under a plan confirmed by a court.

Yes o No o

APPLICABLE ONLY TO CORPORATE REGISTRANTS

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 33,~~482~~536,~~722~~767 (as of ~~August~~May 1015, ~~2006~~2008)

Part I - FINANCIAL INFORMATION

Item 1.

Financial Statements.

(a) Our unaudited financial statements for the ~~second~~first quarter (~~six~~three months ended ~~June~~March 3031, ~~2006~~ 2008), are set forth below. See Item 2 below for Management’'s Discussion and Analysis of Financial Condition and Results of Operations for our first quarter.

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NEW YORK HEALTH CARE, INC.

AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2006

F-2

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NEW YORK HEALTH CARE , INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	June 30, 2006			December 31, 2005
	March 31,			December 31,
	( Unaudited )			(Note 1)
	2008			2007
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,~~546~~262,~~054~~740		$	52,~~522~~246,~~088~~241
Due from lending institution		~~350~~55,~~107~~042			~~198,941~~-
Accounts receivable, net of allowance for uncollectible
Accounts receivable, net of allowance for uncollectible accounts of approximately $555,000 and $576,000, respectively		7,975,996			8,298,837
amounts of $453,000 and $465,000 respectively		7,214,008			7,237,062
Unbilled services		109,118			137,079
Unbilled services		33,082			122,110
Prepaid expenses and other current assets		276,367			120,857
Prepaid expenses and other current assets		1,047,323			388,463
Total current assets		11,679,263			10,803,014
Total current assets		12,190,574			13,468,664
Property and equipment, net		14,970			22,090
Property and equipment, net		167,524			150,052
Goodwill, net		783,000			783,000
Other intangible assets, net		2611,~~645,486~~383			2628,~~830,149~~056
Other assets		~~130~~169,~~312~~415			57181,~~212~~046
Total assets	$	1513,~~916~~258,~~896~~031		$	1712,~~289~~417,~~077~~206
LIABILITIES AND SHAREHOLDERS' EQUITY
LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Current liabilities:
Accrued payroll	$	634,878		$	713,194
Note payable under insurance financing agreement	$	14,508		$	25,054
Accounts payable and accrued expenses		8,925,135			8,732,318
Amounts due to related parties		10,190			27,133
Due to HRA		6,088,273			6,159,912
Accrued payroll		1,054,168			871,171
Total current liabilities		15,648,286			15,605,424
Accounts payable and accrued expenses		6,010,851			5,541,457
Income taxes payable - current		7,150			28,450
Due to HRA		8,920,521			8,754,408
Total current liabilities		16,017,388			15,247,673
Commitment and contingencies
Shareholders' equity:
Shareholders' (deficiency) equity:
Preferred stock, $.01 par value, 5,000,000 shares authorized; Class A Preferred,
Preferred stock, $.01 par value, 5,000,000 shares authorized; Class A Preferred, 590,375 shares issued, none outstanding		-			-
590,375 shares authorized, -0- issued and outstanding at June 30,2006, and December 31, 2005		—			—
Common stock, $.01 par value, 100,000,000 shares authorized; 33,536,767 shares issued and 33,532,722 outstanding		335,368			335,368
Common stock, $.01 par value, 100,000,000 shares authorized;
Additional paid-in capital		37,174,185			37,174,185
33,236,767 shares issued and 33,232,722 outstanding as of June 30, 2006
Common stock and options to be issued		774,220			774,220
and December 31, 2005 respectively:		332,368			332,368
Accumulated deficit		(41,033,657	)		(41,104,767	)
Additional paid-in capital		36,721,148			36,667,281
Common stock and options to be issued		990,220			990,220
Accumulated deficit		(37,765,653	)		(36,296,743	)
Less: Treasury stock (4,045 common shares at cost)		(9,473	)		(9,473	)
Total shareholders' equity		268,610			1,683,653
Total shareholders' (deficiency)		(2,759,357	)		(2,830,467	)
Total liabilities and shareholders' equity	$	15,916,896		$	17,289,077
Total liabilities and shareholders' (deficiency)	$	13,258,031		$	12,417,206

The accompanying notes are an integral part of these consolidated financial statements.

F-31

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

CONSOLIDATED ~~FINANCIAL~~ STATEMENTS OF OPERATIONS

(UNAUDITED)

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

	For The Three Months Ended March 31,
	2008			2007

Net patient service revenue	$	11,021,811		$	11,184,902

Expenses:
Professional care of patients		9,258,663			9,111,496
		1,763,148			2,073,406

Other operating expenses:
General and administrative		1,613,535			1,982,416
Product development		33,069			292,460
Depreciation and amortization		41,749			98,002

Total other operating expenses		1,688,353			2,372,878

Operating income (loss)		74,795			(299,472	)

Other income (expenses):
Interest income		16,213			22,747
Interest expense		(9,898	)		(1,971	)

Other income, net		6,315			20,776

Income (loss) before provision for income taxes		81,110			(278,696	)

Provision for income taxes - current		10,000			51,000

Net income (loss)	$	71,110		$	(329,696	)


Basic and diluted income (loss) per share:
Net income (loss) per share:		$0.00			($0.01	)

Weighted and diluted average shares outstanding		33,536,767			33,536,767

(UNAUDITED)

	For The Three Months Ended						For The Six Months Ended
	June 30,						June 30,
	2006			2005			2006			2005
Net patient service revenue	$	11,018,270		$	10,913,774		$	22,984,884		$	21,666,556
Expenses:
Professional care of patients		9,147,298			9,010,944			18,544,052			17,860,380
Gross Profit		1,870,972			1,902,830			4,440,832			3,806,176
General and administrative		2,242,323			1,940,116			4,228,161			4,472,114
Product development		723,219			528,843			1,398,356			748,813
Bad debts expense		—			248,704			—			283,704
Depreciation and amortization		166,641			161,421			330,369			321,645
Total operating expenses		3,132,183			2,879,084			5,956,886			5,826,276
Operating loss from continuing operations		(1,261,211	)		(976,254	)		(1,516,054	)		(2,020,100	)
Non-operating income (expenses):
Interest income		44,290			15,761			90,275			51,391
Interest expense		—			(1,178	)		(7,863	)		(3,259	)
Non-operating income, net		44,290			14,583			82,412			48,132
Loss from continuing operations before provision for income taxes		(1,216,921	)		(961,671	)		(1,433,642	)		(1,971,968	)
Provision for income taxes		11,100			118,647			35,268			131,906
Loss from continuing operations		(1,228,021	)		(1,080,318	)		(1,468,910	)		(2,103,874	)
Discontinued operations:
Income (loss) from operations of discontinued
component (including gain on sale of assets
of $2,703,718 in 2005) net of tax paid of
$30, 549 and $34,452 respectively		—			2,683,159			—			2,748,446
Income (loss) from discontinued operations		—			2,683,159			—			2,748,446
Net income (loss)	$	(1,228,021	)	$	1,602,841		$	(1,468,910	)	$	644,572
Basic and diluted income (loss) per share:
Loss from continuing operations	$	(0.04	)	$	(0.03	)	$	(0.04	)	$	(0.07	)
Income (loss) from discontinued operations	$	—		$	0.08		$	—		$	0.09
Net income (loss)	$	(0.04	)	$	0.05		$	(0.04	)	$	0.02
Weighted and diluted average shares outstanding		33,232,722			32,947,265			33,232,722			30,536,785

The accompanying notes are an integral part of these consolidated financial statements.

F-42

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

CONSOLIDATED ~~FINANCIAL~~ STATEMENTS OF CASH FLOWS

(UNAUDITED)

(UNAUDITED)

	For The Three Months Ended March 31,
	2008			2007
Cash flows from operating activities:

Net income (loss)	$	71,110		$	(329,696	)

Adjustments to reconcile net (loss) to net cash used in operating activities
Stock-based compensation		-			6,500
Depreciation and amortization		30,117			98,002
Bad debts (recovery)		(21,382	)		-
Abandonment of property and equipment		-			5,652

Changes in operating assets and liabilities
Decrease (increase) in accounts receivable and unbilled services		372,184			(702,241	)
(Increase) decrease in due from lending institution		(55,042	)		167,280
(Increase) in prepaid expenses and other current assets		(155,510	)		(70,684	)
Decrease in other assets		11,631			85,547
(Decrease) in note payable under insurance financing agreement		(10,546	)		-
(Decrease) in due to related parties		(16,943	)		-
Increase in accrued payroll		182,997			140,413
Increase (decrease) in accounts payable and accrued expenses		469,394			(364,328	)
(Decrease) increase in income taxes payable - current		(21,300	)		51,000
Increase in due to HRA		166,113			361,556

Net cash provided by (used in) operating activities		1,022,823			(550,999	)

Cash flows from investing activities:
Additions to intangible assets		(6,324	)		(30,476	)

Net cash (used in) investing activities		(6,324	)		(30,476	)

Net increase (decrease) in cash and cash equivalents		1,016,499			(581,475	)

Cash and cash equivalents at beginning of period		2,246,241			2,469,789

Cash and cash equivalents at end of period	$	3,262,740		$	1,888,314

	For the Six Months Ended June 30,
	2006			2005
Cash flows from operating activities:
Net (loss) income	$	(1,468,910	)	$	644,572
Adjustments to reconcile net (loss) income to net cash
used in operations (excluding the effect of disposition)
Net gain from discontinued operations, net of taxes		—			(2,748,446	)
Noncash compensation		53,867			1,645
Depreciation and amortization		330,369			321,645
Bad debts expense		—			283,704
Changes in operating assets and liabilities, net of effects of disposition
Increase in restricted cash		—			(150,000	)
Decrease in accounts receivable
and unbilled services		112,082			(6,001	)
(Increase) in prepaid expenses and other current assets		(658,860	)		(620,092	)
Decrease (Increase) in due from lending institution		(151,166	)		470,542
Decrease (increase) in other assets		(73,100	)		20,253
Increase (decrease) in accrued payroll		(78,316	)		7,539
Increase in accounts payable and
accrued expenses		192,817			131,441
Increase (decrease) in due to HRA		(71,639	)		267,065
Increase in taxes payable		—			52,361
Net cash used in operating activities of continuing operations		(1,812,856	)		(1,323,772	)
Net cash provided by operating activities of discontinued operations		—			58,849
Total cash used in operating activities		(1,812,856	)		(1,264,923	)
Cash flows from investing activities:
Acquisition of property and equipment		(43,370	)		(53,606	)
Acquisition of intangible assets		(119,808	)		(28,222	)
Net proceeds from sale of discontinued operations		—			2,916,567
Net cash (used in) provided by investing activities		(163,178	)		2,834,739
Cash flows from financing activities:
Net proceeds from issuance of common stock and warrants		—			4,197,396
Net (decrease) increase in cash and cash equivalents		(1,976,034	)		5,767,212
Cash and cash equivalents at beginning of period		5,522,088			2,186,756
Cash and cash equivalents at end of period	$	3,546,054		$	7,953,968

The accompanying notes are an integral part of these consolidated financial statements

~~The accompanying notes are an integral part of these consolidated financial statements.~~F-3

~~F-5~~NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

~~NOTE~~NOTES 1TO -CONSOLIDATED ~~SUMMARY~~FINANCIAL OFSTATEMENTS ~~SIGNIFICANT ACCOUNTING POLICIES:~~ (Unaudited)

March 31, 2008 and 2007

NOTE 1 – ORGANIZATION, RECENT DEVELOPMENTS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Organization and Basis of Consolidation:

New York Health Care, Inc. (“New York Health Care”) was organized under the laws of the State of New York in 1983. New York Health Care provides services of registered nurses and paraprofessionals to patients throughout New York. The BioBalance Corp. (“BioBalance”), a Delaware corporation, was formed in May 2001. BioBalance is a biopharmaceutical company focused on the development of treatments for gastrointestinal diseases that are poorly addressed by current therapies. BioBalance is currently pursuing prescription drug development of its lead product, PROBACTRIX® for the prevention of pouchitis. On March 24, 2006, the Company received approval from the FDA to start Phase II clinical trials. There can be no assurance that BioBalance will be successful in obtaining regulatory approval or in marketing any such products. The consolidated entity, collectively referred to, unless the context otherwise requires, as the “Company”, “we”, “our” or similar pronouns, includes New York Health Care and its wholly-owned subsidiaries, BioBalance and NYHC Newco Paxxon, Inc. D/B/A Helping Hands Healthcare (“Helping Hands”). All financial information prior to the sale of the Company’s home healthcare operations in the State of New Jersey (“NJ Business”) has been restated in order to present the sale of the NJ Business as a discontinued operation. All significant inter-company balances and transactions have been eliminated.

The accompanying ~~interim~~ consolidated financial statements have been prepared byassuming ~~the~~that the Company ~~without~~will ~~audit,~~continue inas ~~accordance~~a ~~with~~going ~~the~~concern. ~~instructions~~The ~~for~~Company’s ~~Form~~recurring ~~10-Q~~losses and ~~pursuant~~negative toworking ~~the~~capital ~~rules~~raises ~~and~~substantial ~~regulations~~doubt ofabout ~~the~~its ~~Securities~~ability ~~and~~to ~~Exchange Commission~~continue ~~(“SEC”)~~as ~~and~~a ~~therefore~~going doconcern. ~~not~~The ~~include~~consolidated ~~all~~financial ~~information~~statements ~~and~~do ~~notes~~not ~~normally~~include ~~provided~~any inadjustments ~~the~~that ~~annual~~might ~~financial~~result ~~statements~~from ~~and~~the ~~should~~outcome beof ~~read~~this inuncertainty. ~~conjunction with the~~Management’s ~~audited~~plans ~~financial~~in ~~statements~~connection ~~and~~with ~~the~~this ~~notes~~matter ~~thereto~~include ~~included~~drawing indown ~~Form~~the ~~10-K~~line of credit ~~New~~as ~~York~~necessary ~~Health~~and ~~Care,~~continuing ~~Inc. for~~ the ~~year~~search ~~ended~~for ~~December~~a ~~31,~~strategic ~~2005~~partner asfor ~~filed~~the ~~on April~~BioBalance ~~17, 2006, with the SEC~~operations.

InThe accompanying interim consolidated financial statements have been prepared by the ~~opinion~~Company ofwithout ~~the Company~~audit, ~~the~~in ~~accompanying~~accordance ~~unaudited~~with ~~financial~~the ~~statements~~instructions ~~contain~~for Form 10-Q ~~all~~pursuant ~~adjustments~~to ~~(which~~the ~~consist~~rules and regulations of ~~normal~~the Securities and ~~recurring~~Exchange ~~adjustments) necessary~~Commission ~~for~~(“SEC”) aand ~~fair~~therefore ~~presentation~~do ofnot ~~the~~include ~~financial~~all ~~statements.~~information ~~The~~and ~~results~~notes ofnormally ~~operations~~provided ~~for~~in the ~~six~~annual ~~months~~financial ~~ended~~statements ~~June~~and ~~30,~~should ~~2006~~be ~~are~~read ~~not~~in ~~necessarily~~conjunction ~~indicative~~with ofthe audited financial statements and the notes thereto included in Form 10-K of ~~results~~New York toHealth beCare, ~~expected~~Inc. for the ~~full~~ year ended December 31, 2007 as filed on April 14, 2008 with the SEC.

In the opinion of the Company, the accompanying unaudited financial statements contain all adjustments (which consist of normal and recurring adjustments) necessary for a fair presentation of the financial statements. The results of operations for the three months ended March 31, 2008 are not necessarily indicative of the results to be expected for the full year.

Recent Developments:

OnAs ~~January~~of March 631, ~~2006~~2008, ~~the~~BioBalance ~~Company~~had ~~entered~~cash ~~into~~on ahand ~~letter~~ of ~~intent~~approximately ~~with~~$180,023 ~~Revival~~all ~~Home~~of ~~Health~~which ~~Care~~was available to fund operations. ~~The~~BioBalance ~~Company~~management ~~was~~estimates ~~negotiating~~that its capital ~~the~~requirements ~~terms~~for an entire year of aoperations ~~definitive~~are ~~agreement~~approximately ~~with~~$5,000,000. ~~Revival~~This amount includes the cost of the initial up front payment for the Phase I/II clinical trial, in the ~~sale~~amount of $3,000,000, for the Company’'s lead ~~home~~product ~~healthcare~~PROBACTRIX® ~~business~~that ~~when~~is itnot ~~was~~expected to be started in 2008. It will be ~~determined~~necessary ~~that~~for ~~there~~the Company to secure additional funding in order for BioBalance to begin the Phase I/II clinical trial, which was aapproved ~~potential~~by ~~problem~~FDA ~~with~~on March 24, 2006. The Company has not been able to obtain additional funding up to the present ~~tax-free~~time ~~nature~~and ofthe BioBalance subsidiary has been operating solely by utilizing funds from the health care operations, which are insufficient for ~~deal~~BioBalance's ~~structure~~needs. ~~that~~Management is ~~required~~continuing into ~~order~~search tofor ~~preserve~~potential ~~all~~funding sources ofbut none have been found thus far. Accordingly, since additional funding from outside sources has not been obtained, the Company’s began scaling back ~~services~~the operations ~~contracts~~of ~~for~~BioBalance at the ~~buyer~~end of November 2006, and BioBalance began operating on a substantially reduced budget in 2007. Management has instituted temporary cutbacks in consultant compensation until such time as additional funds or a strategic partner can be found. There can be no assurances that the Company will be able to raise additional capital in the near term to allow BioBalance to continue its normal level of operations.

The services contract between the Company and New York City constitutes a substantial portion of the Company’s homehealth care business. The services contract terminates upon an assignment of such contract, but would not terminate upon the sale of stock of the Company. Therefore, the Company intends to structure the sale of the home healthcare business as a stock sale to avoid the termination of the services contract with New York City. In order to structure the transaction as a stock sale, management believes that it will be necessary to reorganize the Company into a holding company structure. The reorganization of the Company into a holding company structure involves merging the Company into a whollyF-owned subsidiary of BioBalance, the Company’s wholly-owned subsidiary. As a result of such transaction, all of the Company’s shareholders will exchange their shares of common stock in the Company for shares of common stock of BioBalance. Shareholder approval is required for each of the sale of the Company’s home healthcare business and the reorganization into a holding company structure. As a pre-condition to such transactions, the Company desires further assurances as to the tax-free nature of the reorganization. Accordingly, the Company plans to seek further guidance from the Internal Revenue Service. Following a preliminary meeting with the Internal Revenue Service, the Company feels confident that they will be able to obtain a favorable letter ruling in regard to a transaction. However, in order to apply for the letter ruling the Company will need to have a definitive agreement with a third party buyer for the healthcare business. The Company has instituted communications to ascertain the level of interest at Revival for buying the healthcare business under these conditions. If Revival is not interested, the Company will approach other third parties who previously expressed an interest in buying the home healthcare business. The Company will continue to operate the home healthcare operations in the ordinary course. There can be no assurance that the Company will enter into a definitive agreement or consummate the sale of the Company’s home healthcare business to Revival or any other third party.4

~~F-6~~NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

OnNOTES ~~March 24,~~TO ~~2006,~~CONSOLIDATED ~~BioBalance~~FINANCIAL ~~received~~STATEMENTS ~~approval from the U.S. Food and Drug Administration~~ (~~FDA~~Unaudited) to begin Phase I/II U.S. clinical trials of its proprietary biotherapeutic agent, Probactrix, as a prescription drug for pouchitis. Pouchitis is a debilitating complication that can develop following corrective surgical treatment of ulcerative colitis, in which an ileal reservoir, or pouch, is constructed to enable normal bowel movements after removal of the diseased colon. This ileal reservoir can become inflamed, leading to debilitating gastrointestinal symptoms including diarrhea, incontinence, bleeding, fever and urgency. The cause of pouchitis is not known, though it is believed to result from an immune response to pathogenic bacteria in the pouch flora. There are no currently approved treatments for pouchitis. Current treatment involves short-term and occasionally chronic treatment with antibiotics.

~~The~~March ~~Phase I/II~~31, ~~randomized,~~2008 placebo-controlled, multi-center study will be conducted in approximately 70 antibiotic-dependent pouchitis patients to demonstrate the ability of a prescription formulation of Probactrix to maintain symptomatic response of pouchitis symptoms after antibiotic withdrawal. The principal investigators of the trial are expected to be Darrell S. Pardi, MD, and ~~William J. Sandborn, MD, of the Division of Gastroenterology at the Mayo Clinic in Rochester, Minnesota.~~2007

~~Mr.~~BioBalance ~~O’Donnell,~~ has ~~the~~also ~~Company’s~~commenced ~~CEO,~~preliminary ~~had~~studies aregarding ~~employment~~the ~~agreement~~use ~~with~~of ~~the~~PROBACTRIX® ~~Company~~in ~~which~~the ~~expired~~ treatment onof ~~May~~Celiac 6,disease ~~2006.~~(a ~~The~~dietary ~~Company~~gluten ~~and Mr~~intolerance). ~~O’Donnell~~This ~~are~~study ~~currently negotiating~~was ~~the~~ conducted ~~renewal~~as ofa ~~his~~small ~~employment~~scale ~~agreement.~~pilot ~~There~~study iswhich, nowhile ~~assurance~~not ~~that~~providing ~~such~~data anthat ~~agreement~~ is clinically ~~will~~or bestatistically ~~executed.~~useful Inin ~~June~~demonstrating ~~2006~~efficacy, ~~the~~produced encouraging ~~board~~preliminary ~~awared Mr~~results. ~~O’Donnell~~The aCompany ~~bonus in~~is ~~the~~contemplating ~~amount~~various ofoptions including ~~$112,500~~funding ~~according~~costs relating to ~~the~~clinical ~~terms~~research ofand ~~his~~statistical ~~previous~~analysis ~~agreement~~ for a follow up study.

The Company has taken steps to safeguard the biological strain of PROBACTRIX® by storing it in two separate secure facilities. It is currently evaluating its options for manufacturing of product to enable progress with clinical development.

Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

~~F-7~~Recently Issued Accounting Pronouncements:

~~Recent~~In ~~Issued~~December ~~Accounting~~2007, ~~Pronouncements~~the FASB issued SFAS No. 141 (revised 2007), "Business Combinations." SFAS 141(R) broadens the guidance of SFAS 141, extending its applicability to all transactions and other events in which one entity obtains control over one or more other businesses. It broadens the fair value measurement and recognition of assets acquired, liabilities assumed, and interests transferred as a result of business combinations. SFAS 141(R) expands on required disclosures to improve the statement users' abilities to evaluate the nature and financial effects of business combinations. SFAS 141(R) is effective for our fiscal year beginning January 1, 2009. The adoption of SFAS 141(R) is not expected to have a material impact on the Company's financial position, results of operations or cash flows.

In ~~March 2006~~December 2007, the FASB issued SFAS No. ~~156~~160, ~~Accounting~~"Noncontrolling Interests ~~for~~in ~~Servicing~~Consolidated of Financial ~~Assets,~~ Statements—an ~~Amendment~~amendment of ~~SFAS~~ARB No. ~~140~~ 51. " SFAS 160 ~~No.~~requires ~~156~~that ~~requires~~a ~~separate~~noncontrolling ~~recognition of~~interest in a ~~servicing~~subsidiary ~~asset~~be reported as equity and athe ~~servicing~~amount ~~liability~~of ~~each~~consolidated ~~time~~net anincome ~~entity~~specifically ~~undertakes~~attributable ~~and obligation~~ to the ~~service~~noncontrolling ainterest ~~financial~~be ~~asset~~identified byin ~~entering~~the ~~into~~consolidated ~~a servicing~~financial ~~contract~~statements. ~~This~~It ~~statement~~ also ~~requires~~calls ~~that~~for ~~servicing~~consistency ~~assets~~in ~~and~~the ~~liabilities~~manner of reporting changes bein ~~initially~~the ~~recorded~~parent's atownership ~~fair~~interest ~~value~~ and ~~subsequently~~requires ~~adjusted~~fair tovalue ~~the~~measurement ~~fair~~of ~~value~~any ~~at the~~noncontrolling ~~end~~equity ofinvestment ~~each~~retained ~~reporting~~in ~~period~~a deconsolidation. ~~This~~SFAS ~~statement~~160 is effective infor our fiscal ~~years~~year beginning January 1, 2009. We have not yet ~~beginning~~determined ~~after~~the ~~September~~impact 15of adopting SFAS 160 on the Company's financial position, results ~~2006.~~of operations or cash flows.

In ~~February~~ June, 2006, the ~~Financial Accounting Standards Board (“~~FASB”) issued ~~SFAS~~Interpretation NONo. 48, ~~155,~~ Accounting for ~~Certain~~Uncertainty ~~Hybrid~~in ~~Financial~~Income ~~Instruments-~~Taxes, Anan ~~Amendment~~Interpretation of FASB Statement No. 109, ~~133~~Accounting ~~and~~for ~~140.~~Income ~~The~~Taxes (FIN48), to ~~purpose~~create ofa ~~SFAS~~single ~~statement~~model ~~No.~~to ~~155~~address isaccounting tofor ~~simplify~~uncertainty ~~the~~in tax positions. FIN 48 clarifies the accounting for ~~certain~~income ~~hybrid~~taxes by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial ~~instruments~~statements. byFIN ~~permitting~~48 ~~fair~~also ~~value~~provides guidance on derecognition, ~~re-~~measurement, ~~for~~classification, ~~any~~interest, ~~hybrid~~and ~~financial~~penalties, ~~instrument~~accounting ~~that~~in ~~contains~~interim periods, andisclosure ~~embedded~~and transition. The Company adopted FIN 48 as of ~~derivative~~January 1, 2007. Based on our evaluation, we have concluded that ~~otherwise~~there ~~would~~are no ~~require~~significant ~~bifurcation~~uncertain tax positions requiring recognition in our financial statements. ~~SFAS~~Our Noevaluation was performed for the tax years which remain subject to examination by major tax jurisdictions as of December 31, 2007. ~~155~~We ~~also~~may from ~~eliminates~~time ~~the~~to ~~restriction~~time onbe ~~passive~~assessed ~~derivative~~interest ~~instruments~~or ~~that~~penalties aby ~~qualifying~~major tax jurisdictions, ~~special-purpose~~although ~~entity~~any ~~may~~such ~~hold.~~assessments ~~SFAS~~historically Nohave been minimal and immaterial to our financial results. ~~155~~In isthe ~~effective~~event we have received an assessment for ~~all~~interest and/or penalties, it has been classified in the financial statements as selling, ~~instruments~~general ~~acquired~~and oradministrative ~~issued~~expense. ~~after~~The ~~the~~Company ~~beginning~~is ofcurrently ~~any~~subject ~~entity's~~to ~~first~~a ~~fiscal~~three year ~~beginning~~statue ~~after~~of ~~September~~limitations ~~15,~~by ~~2006~~major tax jurisdictions. The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, New York State, New York City and New Jersey.

InNOTE ~~December~~ 2 ~~2004, the FASB issued SFAS No. 123 (revised 2004), “Share~~-~~Based Payment,”~~ orEARNINGS ~~SFAS~~AND ~~No.~~LOSS ~~123R.~~PER SFAS No. 123R, which replaces SFAS No. 123 and supersedes APB Opinion No. 25, requires that compensation cost relating to share-based payment transactions be recognized in the financial statements, based on the fair value of the equity or liability instruments issued. On April 14, 2005, the SEC staff postponed implementation of SFAS No. 123 (R) and it is effective for the Company as of the beginning of the first interim or annual reporting period that begins after December 15, 2005 and applies to all awards granted, modified, repurchased or cancelled after the effective date. The Company adopted this statement as of January 1, 2006 (See Note 6 ). SHARE:

~~NOTE~~Basic 2 earnings -or ~~LOSS~~loss ~~PER~~per ~~SHARE:~~share excludes dilution and is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding for the period.

Basic loss per share excludes dilution and is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding for the period.F-5

~~Diluted~~NEW ~~earnings~~ YORK ~~per~~HEALTH ~~share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period~~CARE, ~~adjusted to reflect potentially dilutive securities~~INC. ~~Due~~AND to losses from continuing operations for the three and six months ended June 30, 2006 and 2005, potential common stock attributable to options and warrants outstanding of 8,950,112 for the three and six months ended June 30, 2006 and 9,755,156 for the three and six months ended June 30, 2005 were not included in the computation of diluted earnings per share, because to do so would be antidilutive.SUBSIDIARIES

~~F-8~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

March 31, 2008 and 2007

Diluted earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period, adjusted to reflect potentially dilutive securities. For the three months ended March 31, 2008, common stock attributable to options and warrants outstanding of 8,813,659 were not included in the computation of diluted earnings per share because their exercise prices were all greater than the average market price of the common shares. Due to losses for the three months ended March 31, 2007, potential common stock attributable to options and warrants outstanding of 8,732,046 for the three months then ended, were not included in the computation of diluted earnings per share, because to do so would be antidilutive.

NOTE 3 - INTANGIBLE ASSETS:

The major classifications of intangible assets and their respective estimated useful lives are as follows:

June 30, 2006
	March 31, 2008
	Gross Carrying Cost		Accumulated Amortization		Net Carrying Amount
	Gross Amount		Accumulated Amortization		Net Carrying Amount		Estimated Useful Life in Years
Intellectual Property	$	2,706,337	$	1,302,788	$	1,403,549
Patents and trademarks	$	916,519	$	305,136	$	611,383		10
Patents/trademarks		1,273,177		453,116		820,061
Customer base		316,000		316,000		-		5
Non-compete agreement		770,000		442,750		327,250
	$	1,232,519	$	621,136	$	611,383
Customer base		316,000	$	221,374	$	94,626
	$	5,065,514	$	2,420,028	$	2,645,486

	December 31, 2007
	Gross Amount		Accumulated Amortization		Net Carrying Amount		Estimated Useful Life in Years

Patents and trademarks	$	910,195	$	282,139	$	628,056		10
Customer base		316,000		316,000		-		5
	$	1,226,195	$	598,139	$	628,056

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

Accounts payable and accrued expenses consist of the following at:

	June 30, 2006		December 31, 2005
	March 31, 2008		December 31, 2007
Accounts payable	$	~~844~~447,~~797~~846	$	~~867~~492,~~436~~446
Accrued expenses		1309,~~827,493~~066		1505,~~840,910~~995
Accrued settlement per consulting agreement		1,131,100		1,131,100
Accrued employee benefits		54,~~121~~122,~~745~~839		43,~~892~~411,~~872~~916
	$	86,~~925~~010,~~135~~851	$	85,~~732~~541,~~318~~457

F-6

NEW YORK HEALTH CARE, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

March 31, 2008 and 2007

NOTE 5 - LINE OF CREDIT:

~~New~~On ~~York Health~~September ~~Care has a $4~~20,~~000,000~~ ~~line of credit with G.E. Capital Health Care Financial Services (“G.E. Capital”) that expires November 29~~2007, ~~2006. The availability of~~ the ~~line~~Company ofentered ~~credit~~into ~~is based on~~ a ~~formula~~Loan ofand ~~eligible~~Security ~~accounts~~Agreement ~~receivable.~~with CIT ~~The~~Healthcare ~~loan~~LLC, ~~agreement~~as ~~relating~~lender ~~to the line of credit~~ (~~the~~ “~~Loan Agreement~~CIT”). ~~was~~The ~~amended~~term inof ~~2004~~the toLoan ~~allow~~and ~~New York Health Care to lend money to~~Security ~~BioBalance~~Agreement ~~if there~~ is nothree ~~outstanding~~years. ~~loan~~The ~~under~~Loan ~~this~~and ~~Loan~~Security Agreement. ~~The~~provides ~~Loan~~for a ~~Agreement~~revolving ~~has~~line ~~also~~of ~~been~~credit ~~amended~~facility tounder ~~allow~~which ~~New~~the ~~York~~Company ~~Health~~may ~~Care~~borrow, ~~to invest money~~repay inand ~~BioBalance.~~re-borrow Asan ofamount ~~December~~not ~~31,~~exceeding ~~2005,~~the ~~approximately~~lesser of $45,000,000 ~~was~~or ~~available~~the borrowing ~~to the~~base, ~~New~~which ~~York~~is ~~Health~~an ~~Care.~~amount ~~Certain~~that ~~assets~~may ofnot ~~New~~exceed ~~York~~85.00% ~~Health~~of ~~Care~~the ~~collateralize~~estimated net value of the ~~line~~Company's ofEligible ~~credit.~~Accounts, ~~The~~as ~~Loan~~defined ~~Agreement~~in ~~contains~~the ~~various~~agreement. ~~restrictive~~As ~~covenants~~of March ~~which~~31, ~~among other things~~ 2008, ~~require~~approximately ~~that New York Health Care maintain a minimum~~$3,309,000 ~~tangible~~of ~~net worth. Borrowings under~~ the ~~Loan Agreement bear interest at prime~~ ~~plus~~line ~~1½%~~was atavailable ~~June~~for ~~30,~~borrowing ~~2006,~~by (9the Company.~~50%).~~

AtInterest ~~June 30,~~is ~~2006,~~payable ~~there~~on ~~was~~the outstanding principal balance of the credit facility at an annual ~~amount~~rate ~~due~~equal ~~from~~to ~~G.E.~~30-day ~~Capital~~LIBOR ofplus ~~$350,107.~~three ~~This~~and isone-half ~~due~~percent (3.50%), ~~to a~~adjusted ~~lockbox~~monthly ~~being~~in ~~used~~accordance bywith ~~the~~changes ~~New~~in ~~York~~30-day ~~Health~~LIBOR. ~~Care;~~At ~~all~~March ~~collections~~31, ~~are deposited~~2008, ~~with~~the Ginterest rate on this facility was 6.E61%. ~~Capital~~Additionally, ~~and~~the ~~then~~Company ~~transferred~~is required to ~~the~~pay ~~New~~an ~~York~~Unused ~~Health~~Line ~~Care’s~~Fee ~~bank~~and a Collateral Management Fee, the total ~~account~~of which represent 0.50% per annum of the line amount.

The Company's obligations to Lender under the Loan and Security Agreement are secured by a first priority lien on all of the Company's accounts receivable, general intangibles, instruments and documents, and the proceeds thereof. However, no collateral will consist of any assets or property of BioBalance.

Beginning with the quarter ended September 30, 2007, the Company is subject to meeting periodic financial covenants contained in the Loan and Security Agreement. As of March 31, 2008, the Company was in compliance with all of the specified financial covenants.

The Company is prohibited from making dividends, distributions and other withdrawals during the term of the credit facility. However, the Company is permitted to make loans, advances or contributions to its subsidiary, BioBalance provided that certain liquidity requirements are met. The Company is further restricted from mergers and acquisitions, as well as asset sales or dispositions outside the ordinary course of business, provided that such sale restrictions are not applicable to the sale of the stock or assets of BioBalance.

As of March 31, 2008, there was no balance due on this line of credit. For the three months ended March 31, 2008, the company incurred interest expense of $9,311 on this line of credit. As of March 31, 2008, there was a balance due from CIT of $55,042 representing collections deposited with CIT through a lockbox and then transferred to the Company's bank account.

NOTE 6 - STOCK OPTIONS/WARRANTS:

On January 1, 2006 the Company adopted Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), “Share-Based Payment,” (“SFAS 123(R)”). SFAS 123(R) requires the Company to recognize expense related to the fair value of employee stock option awards and to measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. This eliminated the exception to account for such awards using the intrinsic method previously allowable under Accounting Principles Board Opinion No. 25, “Accounting for Stock issued to Employees” (“APB 25”). Prior to January 1, 2006, we accounted for the stock based compensation plans under the recognition and measurement provisions of APB 25, as permitted by SFAS No. 123, “Accounting for Stock-Based Compensation.”

F-9

Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS 123(R), using the modified-prospective-transition method. Under that transition method, compensation cost recognized in 2006 and beyond includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all stock-based payments granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS 123(R). Results for prior periods have not been restated and there is no cumulative effect upon adoption of SFAS 123(R).

The fair value of each option grant is estimated on the date of grant by use of the Black-Scholes option pricing model. Proforma results for the 2005 periods are as follows:

	For the three months ended June 30 2005			For the six months ended June 30 2005
Net income (loss), as reported	$	1,602,841		$	644,572
Less stock-based compensation expense determined under fair value method for all employee stock options, net of tax effect	$	(125,907	)	$	(812,796	)
Proforma net income (loss)	$	1, 476,934		$	(168,224	)
Basic and diluted income (loss) per share, as reported	$	0.05		$	0.02
Basic and diluted income (loss) per share, pro forma	$	0.04		$	(0.01	)

The weighted average fair value and assumptions used to estimate these values are as follows:

F-10

	For the Three Months Ended June 30 2005		For the Six Months Ended June 30 2005
Risk free interest rate		1.6—4.2%		1.6—4.2%
Expected volatility of common stock		88—102%		88—102%
Dividend yield		0%		0%
Expected option term		3-5 yrs		3-5 yrs

During the quarter ended June 30, 2006, no options were granted. During the six months ended June 30, 2006, the following options were granted to directors and to a consultant in accordance with the Company’s 2004 Performance Incentive Plan.

Grant Date	Number of Options		Exercise Price		Expiration Term
January 4, 2006		45,000	$	0.78		5 yrs
March 6, 2006		1,100,000	$	0.78		4 yrs

	For the Three Months Ended June 30 2006		For the Six Months Ended June 30 2006
Risk free interest rate		—		4.30	%
Expected volatility of common stock		—		101	%
Dividend yield		—		0	%
Expected option term		—		3 yrs

The value of the 1,100,000 options granted on March 6, 2006, were accrued at December 31, 2005, in the amount of $ 462,220 as part of the total accrual for the settlement with Emerald Asset.

On July 17, 2006, subsequent to the balance sheet date, the Company issued 250,000 shares and 250,000 options at $0.57, to for investment relations services in accordance with terms of a contract signed on July 6, 2006. The options were valued at $90,375.

Performance Incentive Plan:

On August 31, 2005, the shareholders approved the Company’'s 2004 Incentive Plan, (the “Incentive Plan”). Under the terms of the Incentive Plan, up to 35,~~175~~000,000 shares of common stock may be granted ~~at June 30, 2006~~. The Incentive Plan is administered by the Compensation Committee which is appointed by the Board of Directors. The Committee determines which key employee, officer or director on the regular payroll of the Company, or outside consultants shall receive stock options. Granted options are exercisable after the date of grant in accordance with ~~with~~ the terms of the grant up to ten years after the date of the grant. The exercise ~~exercise~~ price of any incentive stock option or nonqualified option granted under the Incentive Plan may not be less than 100% of the fair market value of the shares of common stock of the Company at the time of the grant.

F-117

On March 26, 1996, the Company’'s Board of Directors adopted the Performance Incentive Plan, (the “Option Plan”). The option plan has substantially the same terms as the Incentive Plan above.

Activity in stock options and warrants, including those outside the Performance Incentive Plan, for the ~~six~~three months ended March ~~June 30~~31, ~~2006,~~ 2008 is summarized as follows:

	Shares Under Options/Warrants			Weighted Average Exercise Price
	Shares Under			Weighted Average
Balance at January 1, 2006		7,906,778		$	0.98
	Options/Warrants			Exercise Price
Options granted		1,145,000			0.78
Balance at January 1, 2008		8,862,046		$	0.88
Options cancelled/expired		(101,666	)		1.10
Options granted		-
Options exercised		—			—
Options cancelled/expired		(48,387	)		3.31
Balance at June 30, 2006		8,950,112		$	0.97
Options exercised		-			-
Options eligible for exercise at
Balance at March 31, 2008		8,813,659		$	0.87
June 30, 2006		8,900,112		$	0.96
Options eligible for exercise at March 31, 2008		8,813,659		$	0.87

The following table summarizes information about options and warrants outstanding and exercisable at June 30, 2006.

Range of Exercise Price	Options/ Warrants Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Options Warrants Exercisable		Weighted Average Options Warrants Exercisable
$3.69		100,000		2.21	$	3.69		100,000	$	3.69
$3.22-3.47		48,387		1.51		3.31		48,387		3.31
$3.14		160,000		6.69		3.14		160,000		3.14
$3.00		33,900		0.42		3.00		33,900		3.00
$3.00		39,166		0.59		3.00		39,166		3.00
$2.55		75,333		1.92		2.55		75,333		2.55
$2.48		200,000		6.99		2.48		200,000		2.48
$2.44		6,667		1.92		2.44		6,667		2.44
$2.13		50,000		7.59		2.13		50,000		2.13
$1.50		51,333		2.48		1.50		51,333		1.50
$1.21		200,000		4.19		1.21		200,000		1.21
$1.20		105,000		4.17		1.20		105,000		1.20
$1.00		200,000		4.92		1.00		150,000		1.00
$0.97		66,667		3.37		0.97		66,667		0.97
$0.89		133,333		4.51		0.92		133,333		0.92
$0.84		75,000		8.94		0.84		75,000		0.84
$0.80		100,000		8.85		0.80		100,000		0.80
$0.78		5,726,993		3.66		0.78		5,726,993		0.78
$0.78		1,145,000		3.72		0.78		1,145,000		0.78
$0.75		133,333		4.03		0.75		133,333		0.75
$0.75		200,000		4.09		0.75		200,000		0.75
$0.50		100,000		8.21		0.50		100,000		0.50
		8,950,112		4.32	$	0.97		8,900,112	$	0.96

F-12

NOTE 7 - COMMITMENTS AND CONTINGENCIES:

On March 6, 2006, the Company entered into a settlement agreement (the “Emerald Settlement Agreement”) with Emerald Asset Management, Inc. (“Emerald”) and ~~Mr.~~Yitz Grossman related to the resolution of disputes under a consulting agreement dated June 1, 2001 between the Company and Emerald.

Pursuant to the Emerald Settlement Agreement and in order avoid the cost and uncertainty of litigation, the Company agreed to (i) the immediate payment of $700,000 to Emerald, (ii) payment of $22,000 per month for eighteen months beginning January 1, 2006, (iii) the issuance of 400,000 shares of common stock, (iv) options to purchase 1,100,000 shares of common stock at $0.78 per share until March 1, 2010 and (v) health insurance for Grossman and his family for the eighteen month period ending June 30, 2007 amounting to approximately $35,100. In return, Emerald and Grossman have executed a general release of all claims they may have against the Company. The Company has not paid any of this liability and has expensed $1,545,931 for the above settlement during the year ended December 31, 2005. The Company has recorded a liability of $1,131,100 and common stock and options to be issued valued at $774,220 as of December 31, 2005. On April 17, 2006, the Company and Emerald amended the Emerald Settlement Agreement so that the cash portion of the settlement would not be paid until such time as the Company receives new funds from any source. ~~At June 30, 2006, the Company has not made any cash payment to Emerald or issued any stock or options called for under the settlement Agreement.~~

On March 9, 2006, the Company entered into a final settlement agreement (the “Corval Settlement Agreement”) with Mark Olshenitsky related to the resolution of disputes under a consulting agreement dated April 14, 2003, between the Company and Corval International, Inc. (“Corval”).

Pursuant to the Corval Settlement Agreement and in order to avoid the cost and uncertainty of litigation, the Company agreed to issue 300,000 shares of Common Stock to Olshenitsky in return for a general release of all claims Corval and Olshenitsky may have against the Company. ~~The Company has recorded a liability in the amount of $216,000 as of December 31, 2005.~~

~~NOTE~~On August 821, -2006, ~~DISCONTINUED~~the ~~OPERATIONS~~Company unilaterally rescinded the settlement between the Company and Emerald Asset and Yitz Grossman. The rescission of the settlement by the Company was done without the consent of Emerald Asset and Yitz Grossman. Accordingly there may be future litigation brought against the Company by Emerald Asset and Yitz Grossman to seek enforcement of the agreement. The Company continues to retain the accrual for the settlement agreement on its books in its entirety. If there is litigation brought by Emerald Asset and Yitz Grossman to enforce the settlement agreement, there can be no assurance that at a future time the accrual that was recorded would be sufficient to offset amounts resulting from the future litigation. On April 24, 2008, the Company was contacted by counsel for Yitz Grossman, demanding that the Company perform its obligations under the settlement agreement. The Company is presently considering its options and has not yet responded to this demand.

On April 11, 2005, the Company entered into an agreement to sell certain assets of Helping Hands for $3,000,000 to Accredited Health and a formal closing for the sale, which was subject to only an orderly transition of the assets, occurred on May 22, 2005. Helping Hands was part of the New York Health Care segment.F-8

InNEW ~~connection~~YORK ~~with~~HEALTH ~~the sale~~CARE, ~~the Company recognized an after tax gain of approximately $2~~INC.7 ~~million~~AND ~~on the transaction, net of taxes, which was included in income from discontinued operations for the year ending December 31, 2005.~~ SUBSIDIARIES

~~F-13~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

~~Operating~~March ~~results~~31, of2008 ~~our~~and ~~discontinued operations are shown below:~~2007

~~DISCONTINUED~~NOTE ~~OPERATIONS~~8 - INCOME TAXES:

~~CONSOLIDATED~~The ~~STATEMENTS~~temporary OFdifferences ~~OPERATIONS~~that give rise to deferred tax assets are impairment of intangible assets for financial statement book purposes over tax purposes, the direct write-off method for receivables, using accelerated methods of amortization and depreciation for property and equipment for tax purposes, and using statutory lives for intangibles for tax purposes. Also included in the deferred tax asset is a net operating loss carryforward. At March 31, 2008 and December 31, 2007, the Company has computed a deferred tax asset in the amount of approximately $9,255,000 and $9,244,000, respectively. A full valuation allowance has been recorded against the net deferred tax assets because of the unlikelihood that those assets will be realized in the foreseeable future. The valuation allowance increased by $11,000 during the three months ended March 31, 2008.

	For the Three Months Ended June 30, 2006		For the Three Months Ended June 30, 2005			For the Six Months Ended June 30, 2006		For the Six Months Ended June 30, 2005
Net patient service revenue	$	—	$	978,253		$	—	$	2,687,876
Professional care of patients		—		690,661			—		1,865,255
General and administrative		—		277,602			—		731,724
Depreciation and amortization		—		—			—		11,717
Gain on sale of assets		—		(2,703,718	)		—		(2,703,718	)
Provision for taxes		—		30,549			—		34,452
Income from discontinued operations	$	—	$	2,683,159		$	—	$	2,748,446

NOTE 9 - SUPPLEMENTAL CASH FLOW DISCLOSURES:

NOTE 9 - INCOME TAXES:

	For The Three Months Ended
	March 31
	2008		2007
Supplemental cash flow disclosures:
Cash paid during the period for:
Interest	$	9,898	$	1,971
Income taxes	$	31,300	$	-

The temporary differences that give rise to deferred tax assets are impairment of intangible assets for financial statement book purposes over tax purposes, the direct writeF-off method for receivables, using accelerated methods of amortization and depreciation for property and equipment for tax purposes, and using statutory lives for intangibles for tax purposes. Also included in the deferred tax asset is a net operating loss carryforward. At June 30, 2006 and December 31, 2005, the Company has computed a deferred tax asset in the amount of approximately $6,400,000 and $5,138,000, respectively. A full valuation allowance has been recorded against the net deferred tax assets because it is not more likely than not that such assets will be recognized in the foreseeable future. The valuation allowance increased by $1,262,000 during the six months ended June 30, 2006.9

~~NOTE~~NEW 10 YORK -HEALTH ~~SUPPLEMENTAL~~CARE, ~~CASH~~INC. ~~FLOW~~AND ~~DISCLOSURES:~~SUBSIDIARIES

	For The Six Months Ended June 30
	2006		2005
Supplemental cash flow disclosures:
Cash paid during the period for:
Interest	$	7,863	$	3,259
Income taxes	$	—	$	40,888

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

~~F-14~~March 31, 2008 and 2007

NOTE 11 10 - SEGMENT REPORTING:

The Company has two reportable business segments: New York Health Care, a home ~~healthcare~~ health care agency that provides a broad range of health care support services to patients in their homes, and BioBalance, a segment that is developing a probiotic agent for the treatment of gastrointestinal disorders. BioBalance has not generated any revenue as of ~~June~~March 3031, ~~2006~~2008.

	New York HealthCare			BioBalance			Total Consolidated
	Health Care Segment			BioBalance Segment			Elimination of Intersegment Activity			Consolidated
Six Months Ended June 30, 2006
Three Months Ended March 31, 2008
Revenue:
Net revenue	$	22,984,884		$	—		$	22,984,884
Net patient service revenue	$	11,021,811		$	-		$	-		$	11,021,811
Sales		—			—			—
Total revenue	$	11,021,811		$	-		$	-		$	11,021,811
Total revenue	$	22,984,884			—		$	22,984,884
Net income (loss) before provision for income taxes		236,377		$	(155,267	)	$	-		$	81,110
Total Assets	$	12,799,195		$	3,117,701		$	15,,916,896
Total assets	$	19,062,591		$	21,142,860		$	(26,947,420	)	$	13,258,031
Loss from continuing operations	$	1,124,350		$	(2,593,260	)	$	(1,468,910	)
Three Months Ended March 31, 2007
Six Months Ended June 30, 2005
Revenue:
Revenue:
Net patient service revenue	$	11,184,902		$	-		$	-		$	11,184,902
Net revenue	$	21,666,556		$	—		$	21,666,556
Total revenue	$	11,184,902		$	-		$	-		$	11,184,902
Sales		—			—			—
Net income (loss) before provision for income taxes		408,198		$	(686,894	)	$	-		$	(278,696	)
Total revenue	$	21,666,556		$	—		$	21,666,556
Total assets	$	15,313,417		$	6,491,797		$	21,805,214
Loss from continuing operations	$	(119,750	)	$	(1,984,124	)	$	(2,103,874	)
Three Months Ended June 30, 2006
Revenue:
Net revenue	$	11,018,270		$	—		$	11,018,270
Sales		—			—			—
Total Revenue	$	11,018,270		$	—		$	11,018,270
Loss from continuing operations	$	64,602		$	(1,292,623	)	$	(1,228,021	)
Three Months Ended June 30, 2005
Revenue:	$	10,913,774		$	—		$	10,913,774
Loss from continuing operations	$	(115,160	)	$	(965,158	)	$	(1,080,318	)

F-1510

Item 2: MANAGEMENT'S DISCUSSION & ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

Forward Looking Statements

Certain information contained in this report is forward-looking in nature. All statements in this report, including those made by the Company and its subsidiaries (“we”, “our”, or the “Company”), other than statements of historical fact, are forward-looking statements. Examples of forward-looking statements include statements regarding the Company’'s future financial condition, operating results, business and regulatory strategies, projected costs, services, research and development, competitive positions and plans and objectives of management for future operations. These forward-looking statements are based on management’'s estimates, projections and assumptions as of the date hereof and include the assumptions that underlie such statements. Forward-looking statements may contain words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology. Any expectations based on these forward-looking statements are subject to risks and uncertainties and other important factors, including those discussed in Item 2 - Management’'s Discussion and Analysis of Financial Condition and Results of Operations. Other risks and uncertainties are disclosed in the Company’'s prior SEC filings. These and many other factors could affect the Company’'s future financial operating results, and could cause actual results to differ materially from expectations based on forward-looking statements made in this report or elsewhere by the Company or on its behalf. The Company assumes no obligation to update such statements.

All references to fiscal year apply to the Company’'s fiscal year which ends on December 31, ~~2006~~2008.

Overview

We are currently engaged in two industry segments, the delivery of home healthcare services (sometimes referred to as the “home healthcare business”) and the development of proprietary biotherapeutic agents for the treatment of various gastrointestinal (“GI”) disorders, through our acquisition of BioBalance.

The Company is a New York corporation incorporated in 1983. The Company’'s principal executive office is 1850 McDonald Avenue, Brooklyn, New York 11223, telephone 718-375-6700. ~~The Company intends to change its principal executive offices to the offices of BioBalance when and if the home healthcare business is sold.~~

Critical Accounting Policies

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited Consolidated Financial Statements and accompanying notes. Estimates are used for, but not limited to, the accounting for allowance for doubtful accounts and potential impairment of goodwill and other intangibles.. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the ~~circumstances.~~ circumstances. Actual results could differ from these estimates under different ~~assumptions~~ assumptions or conditions.

The Company believes that there have been no significant changes, during the three month period ended ~~June~~March 3031, ~~2006~~2008, to the items disclosed as critical ~~accounting~~ accounting policies and estimates in Managements Discussion and Analysis of ~~Financial~~ Financial Condition and Results of Operations in the Company’'s Annual Report on Form 10-K for the year ended December 31, ~~2005~~2007.

Results of Operations

~~THREE~~Three ~~AND~~ Months ~~SIX MONTHS ENDED JUNE 30~~Ended March 31, ~~2006~~ ~~COMPARED WITH THREE AND~~2008 ~~SIX MONTHS ENDED JUNE 30~~Compared With Three Months Ended March 31, ~~2005~~ 2007

~~The~~Revenues ~~following table reflects the results of operations~~ for the three ~~and six~~ months ended ~~June~~March 3031, ~~2006~~2008 ~~and~~decreased by $163,091 (1.5%) to $11,021,811 from $11,184,902 for the three ~~and six~~ months ended ~~June~~March 3031, ~~2005~~2007. All ~~for~~of ~~each~~the ~~business~~revenues ~~segment~~are generated from the home health care operations.

	Three Months Ended June 30, 2006								Three Months Ended June 30, 2005
	BioBalance Segment			Healthcare Segment		Total			BioBalance Segment			Healthcare Segment			Total
Revenues	$	—		$	11,018,270	$	11,018,270		$	—		$	10,913,774		$	10,913,774
Cost of patient care		—			9,147,298		9,147,298			—			9,010,944			9,010,944
SG&A		569,983			1,838,981		2,408,964			433,525			1,916,716			2,350,241
Product Development		723,219			—		723,219			528,843			—			528,843
Loss from continuing operations	$	(1,292,623	)	$	64,602	$	(1,228,021	)	$	(951,359	)	$	(128,959	)	$	(1,080,318	)

Cost of professional care of patients for the three months ended March 31, 2008 increased by $147,167 (1.6%) to $9,258,663 from $9,111,496 for the three months ended March 31, 2007. As a percentage of revenue the cost of sales was 84% for the three months ended March 31, 2008 as compared to 81% for the three months ended March 31, 2007.

	Six Months Ended June 30, 2006								Six Months Ended June 30, 2005
	BioBalance Segment			Healthcare Segment		Total			BioBalance Segment			Healthcare Segment			Total
Revenues	$	—		$	22,984,884	$	22,984,884		$	—		$	21,666,556		$	21,666,556
Cost of patient care		—			18,544,052		18,544,052			—			17,860,380			17,860,380
SG&A		1,198,116			3,360,418		4,558,534			1,233,078			3,844,385			5,077,463
Product Development		1,398,356			—		1,398,356			748,813			—			748,813
Loss from continuing operations	$	(2,593,260	)	$	1,124,350	$	(1,468,910	)	$	(1,984,121	)	$	(119,750	)	$	(2,103,871	)

~~The~~Selling, ~~following~~general ~~analyses~~and ~~the~~administrative ~~breakdown~~expenses of("SG&A") for the ~~operations~~home ~~between~~health care segment for the ~~two~~three ~~business~~months ended March 31, 2008 decreased by $140,487 ~~segments~~(8.4%) to $1,527,831 from $1,668,318 for of the three ~~home~~months ~~healthcare~~ended ~~segment~~March ~~and~~31, ~~the~~2007. ~~BioBalance~~This ~~segment~~decrease is primarily due to reductions of professional fees.

2Selling, general and administrative expenses ("SG&A") for the BioBalance segment for the three months ended March 31, 2008 decreased by $228,394 or 72.7% to $85,704 from $314,098 for the three months ended March 31, 2007. This decrease is due to cost reductions resulting from scaling back BioBalance operations due to lack of available funding.

Product development costs for the BioBalance segment ~~Segment~~for the three months ended Mrch 31, 2008 decreased by $259,391 or 88.7% to $33,069 for the three months ended March 31, 2008 as compared to $292,460 for the three months ended March 31, 2007. The decrease is due to temporary suspension of the development work required for the IND for PROBACTRIX® that the BioBalance segment received approval for Phase I/II testing on March 24, 2006 due to lack of available funding.

ToThe net income of $71,110 for the three months ended March ~~date~~31, ~~BioBalance~~2008, ~~has~~includes ~~not~~net ~~generated~~income ~~any~~of ~~revenues~~$226,377 from the operations of the home health care segment and ~~does~~offset ~~not~~by ~~have~~a ~~any~~net ~~cost~~loss of ~~sales~~$155,267 from the BioBalance segment, ~~expense~~which to date has not generated any revenue.

~~Selling,~~The ~~general and administrative expenses ("SG&A") for the three months ended June~~net ~~30,~~loss ~~2006,~~of ~~increased approximately 31% to approximately~~ $~~570~~329,~~000 from~~696 ~~approximately $434,000~~ for the three months ended ~~June~~March 3031, ~~2005. For the six months ended June 30~~2007, ~~2006,~~includes ~~SG&A~~net ~~decreased~~income 3%of ~~to approximately~~ $1357,198~~,000~~ from ~~approximately~~the operations ~~$1,233,000~~of ~~for~~ the ~~six~~home ~~months~~health ~~ended~~care ~~June~~segment ~~30,~~and ~~2005.~~offset ~~The decrease~~by isa ~~primarily~~net ~~due~~loss ~~to the transferring~~ of $686,894 from ~~certain costs to~~ the ~~corporate~~ ~~parent~~BioBalance ~~that~~segment, ~~relate~~which to ~~time~~date ~~spent~~has onnot ~~corporate~~generated ~~matters~~any ~~by BioBalance personnel~~revenue.

Product development costs for the BioBalance segment for the three months ended June 30, 2006, were $723,000 as compared to $529,000 for the three months ended June 30, 2005. For the six months ended June 30, 2006, product development costs were $1,398,000 as compared to $749,000 for the six months ended June 30, 2005. The increase is due to the development work required for the IND for PROBACTRIX that the BioBalance received approval for Phase I/II testing on March 24, 2006 and to support clinical trials being conducted overseas.

For the three months ended June 30, 2006, the operations of the BioBalance segment showed a loss from operations of $1,293,000 and for the three months ended June 30, 2005, showed a net loss of $951,000. For the six months ended June 30, 2006 the BioBalance segment had a loss from operations of $2,593,000, as compared to a loss from operations of $1,984,000 for the six months ended June 30, 2005.

Home Healthcare Segment

Revenues for the three months ended June 30, 2006 increased to approximately $11,018,000 from approximately $10,914,000 for the three months ended June 30, 2005. For the six months ended June 30, 2006, revenues increased to $22,985,000 from $21,667,000 at June 30, 2005. The revenue in the home health care segment includes a reversal of debt from HRA in the amount of approximately $704,000 in the quarter ended March 31, 2006, which relates to funds that HRA agreed not collect for their fiscal year 2002. The Company had previously accrued this amount as due to HRA.

Cost of professional care of patients for the three months ended June 30, 2006, increased to approximately $9,147,000 from approximately $9,011,000 for the three months ended June 30, 2005. For the six months ended June 30, 2006 cost of professional care of patients increased to $18,544,000 from $17,860,000 at June 30, 2005. As a percentage of revenue the cost of sales remained constant from period to period for the three and six months when taking into account the reversal of debt from HRA in the amount of $704,000 for the six month period.

Selling, general and administrative expenses ("SG&A") for the three months ended June 30, 2006, decreased approximately 4% to approximately $1,838,000 from approximately $1,917,000 for the three months ended June 30, 2005. For the six months ended June 30, 2006, SG&A decreased 13 % to approximately $3,360,000 from approximately $3,844,000 for the six months ended June 30, 2005. This decrease is due to the reduction of personnel costs and general operating costs at the home health care operations.

The increase for operations for the home healthcare segment for the three months ended June 30, 2006, was approximately $64,000 as compared to a loss from operations of $129,000 for the three months ended June 30, 2005. For the six months ended June 30, 2006 the income from the operations of the home health care segment was $1,124,000 as compared to a loss from operations of $120,000 for the six months ended June 30, 2005. The factors affecting the income of the home health care division were the sale of the New Jersey operations in the second quarter of 2005 and a one time reversal of debt from HRA in the amount of approximately $704,000 in the first quarter of 2006.

Liquidity and Capital Resources

~~Home~~At ~~Healthcare~~March 31, ~~Segment~~2008, the Company had no long-term debt. Future minimum rental commitments for all non-cancelable lease obligations at March 31, 2008, are as follows:

At June 30, 2006, the Company had no long-term debt. Future minimum rental commitments for all non-cancelable lease obligations at June 30, 2006, are as follows:

	Payment due by period
Contractual Obligations	Total		Less than 1 year		2 years		3-5 years		More than 5 years
Long-term debt obligations	$	-	$	-	$	-	$	-	$	-
Capital lease obligations		-		-		-		-		-
Operating lease obligations*		688,000		306,000		262,000		120,000		-
Purchase obligations		-		-		-		-		-
Total	$	688,000	$	306,000	$	262,000	$	120,000	$	-

	Payment due by period
Contractual Obligations	Total		Less than 1 year		1-3 years		More than 3-5 years		5 years
Long-term debt obligations	$	—	$	—	$	—	$	—	$	—
Capital lease obligations		—		—		—		—		—
Operating lease obligations*		1,801,048		427,788		784,637		588,623		—
Purchase Obligations		—		—		—		—		—
Total	$	1,801,048	$	427,788	$	784,637	$	588,623	$	—

These leases also generally contain provisions allowing rental obligations to be accelerated upon default in the payment of rent or the performance of other lease obligations. These leases generally contain provisions for additional rent based upon increases in real estate taxes and other cost escalations.

* These leases also generally contain provisions allowing rental obligations to be accelerated upon default in the payment of rent or the performance of other lease obligations. These leases generally contain provisions for additional rent based upon increases in real estate taxes and other cost escalations. The lease for the office space for BioBalance is included in the above amounts.

The Company has no off-balance sheet arrangements and has not entered into any transactions involving unconsolidated, limited purpose entities or commodity contracts.

The sources of liquidity and capital resources for the home healthcare segment are internally generated funds, ~~cash on hand~~ and ~~amounts~~cash ~~available~~in ~~under a $4,000,000 revolving credit facility with G~~banks.~~E. Capital Health Care Services relating exclusively to the home healthcare segment. Currently there is no outstanding indebtedness under this facility.~~

~~Loans~~The ~~under~~Company ~~this~~has a revolving ~~credit~~line ~~loan~~of credit facility, under which ~~expires~~the inCompany ~~November 2006,~~ may beborrow, ~~used~~repay ~~only for working capital of the New York Health Care’s home healthcare business~~ and ~~other~~re-borrow ~~costs~~an ~~arising~~amount innot ~~the~~exceeding ~~ordinary course of that business. New York Health Care’s obligations to pay~~ the ~~principal~~lesser of, ~~and interest on~~$5, ~~loans advanced under this facility~~000,000 ~~are~~or ~~secured by substantially all~~ the ~~assets~~borrowing ofbase, ~~the~~which ~~New York~~is ~~Health~~an ~~Care’s home healthcare~~amount ~~business,~~that ~~and~~may not byexceed ~~any assets of BioBalance. Borrowings under the facility are permitted to the extent of a borrowing base of up to~~ 85.00% of ~~“qualified~~ ~~accounts receivable” of~~ the ~~New~~ ~~York~~estimated ~~Health~~net ~~Care’s~~value ~~home healthcare business and there are no events~~ of ~~default under~~ the ~~relevant loan documents subject to the lender’~~Company's ~~right~~Eligible toAccounts, ~~reduce~~as ~~the~~defined ~~borrowing~~in ~~base by applying~~the ~~a liquidity factor percentages formula based upon a calculation relating to recent collection histories of certain classes of qualified accounts receivable~~agreement. ~~Currently,~~ ~~application~~As of ~~the~~March ~~liquidity factors percentage formula results in 97% of qualified accounts receivable being part of the borrowing base. Accordingly~~31, ~~at December 31~~2008, ~~2005~~approximately ~~the amount available for borrowing under this facility was~~ $43,~~000~~309,000~~. The agreement contains various restrictive covenants,~~ ~~which~~of ~~amongst other things, require that~~ the ~~New~~ ~~York~~line ~~Health~~was ~~Care~~available ~~to maintain a~~for ~~minimum~~borrowing ~~tangible~~by ~~net~~the ~~worth~~Company. ~~greater~~There ~~than~~was ~~$500,000.~~no ~~New York~~balance ~~Health~~due ~~Care utilizes~~on ~~the~~this ~~line~~facility as of ~~credit~~March ~~from time to time~~31, ~~and at the present time there is no balance outstanding~~2008.

~~New~~For ~~York Health Care~~the ~~has amended~~three ~~its~~months ~~loan~~ended ~~agreement~~March ~~relating~~31, to2008, ~~the~~net ~~revolving~~cash ~~credit~~provided ~~facility~~by tooperating ~~allow~~activities itwas $1,022,823 toas compared ~~lend money~~ to ~~its~~cash ~~BioBalance~~used ~~subsidiary~~by ifoperating ~~there~~activities isof ~~no loan outstanding~~$550,999 ~~under~~during the ~~revolving~~three ~~credit~~months ~~facility.~~ended ~~The~~March ~~loan~~31, ~~agreement~~2007, ~~has~~an ~~also~~improvement ~~been~~of ~~amended to~~$1,573,822. ~~allow the New York Health Care to invest money in BioBalance.~~

~~For~~Net ~~the~~cash ~~six months ended June 30, 2006, net cash~~ used in ~~operating~~investing activities ~~was approximately~~for ~~$1,813,000 as compared to cash used by operating activities of approximately $1,324,000 during~~ the ~~six~~three months ended ~~June~~March 3031, ~~2005,~~2008 ~~an increase~~and of2007 was $~~489~~6,~~000. The~~ 324 and $~~489~~30,~~000~~476 respectively ~~change~~consisting ~~was~~primarily ~~principally~~of ~~due~~the toacquisition aof ~~increased~~intangible ~~net~~assets. ~~loss.~~

~~Net~~Days ~~cash~~Sales Outstanding ("DSO") is a measure of the average number of days taken ~~used~~by the inCompany ~~investing~~to ~~activities~~collect ~~for~~its account receivable, calculated from the date services are billed. For the three months ended ~~June~~March 3031, ~~2006~~2008, ~~totaled approximately~~the ~~$163,000~~DSO ~~and~~of ~~consisted~~the ~~principally~~home care segment of the ~~acquisition~~Company ofwas 70, ~~intangible~~compared ~~assets.~~to 68 days for the three months ended March 31, 2007.

Days Sales Outstanding ("DSO") is a measure of the average number of days taken by the Company to collect its account receivable, calculated from the date services are billed. For the three months ended June 30, 2006, the DSO of the home care segment of the Company was 67, compared to 73 days for the three months ended June 30, 2005.

BioBalance Segment

As of ~~June~~ March 3031, ~~2006~~2008, BioBalance had cash on hand of approximately $180,023 all of which was available to fund operations. BioBalance management estimates that its capital requirements for an entire year of operations are approximately $5,000,000. This amount includes the cost of the initial up front payment for the Phase I/II clinical trial, in the amount of $3,000,000, for the Company's lead product PROBACTRIX® that is not expected to be started in 2008. It will be necessary for the Company to secure additional funding in order for BioBalance to begin the Phase I/II clinical trial, which was approved by FDA on March 24, 2006. The Company has ~~generated~~not nobeen ~~revenues~~able to obtain additional funding up to the present time and the BioBalance subsidiary has nobeen ~~accounts~~operating solely by ~~receivable~~ utilizing funds from the health care operations, which are insufficient for BioBalance's needs. ~~The~~Management ~~assets~~is continuing to search for potential funding sources but none have been found thus far. Accordingly, since additional funding from outside sources has not been obtained, the Company began scaling back the operations of BioBalance ~~consist~~at ~~mainly~~the end of ~~intangibles~~November ~~related~~2006, and BioBalance began to operating on a substantially reduced budget in 2007. Management has instituted temporary cutbacks in consultant compensation until such time as additional funds or a strategic partner can be found. There can be no assurances that the Company ~~patents~~will itbe ~~holds~~able onto raise additional capital in the near term to allow BioBalance to continue its ~~lead~~normal ~~product~~level ~~PROBACTRIX~~of operations.

~~As of June 30, 2006,~~ BioBalance ~~had cash on hand of approximately $170,606 all of~~ ~~which~~ has ~~was~~also ~~available~~commenced topreliminary ~~fund~~studies ~~operations.~~regarding ~~BioBalance estimates that its capital requirements for~~ the ~~remainder~~use of ~~2006~~PROBACTRIX® ~~will~~in ~~be approximately $5,335,000. This~~the ~~amount~~ treatment ~~includes the cost~~ of ~~the~~Celiac ~~Phase~~disease ~~I/II~~(a ~~clinical~~dietary ~~trial~~gluten ~~for~~intolerance). ~~the~~This ~~Company’s~~study ~~lead~~was ~~product~~ conducted ~~PROBACTRIX~~as ~~that~~a ~~was~~small ~~approved~~scale onpilot ~~March~~study 24which, ~~2006.~~while ~~This~~not ~~estimate~~providing ~~assumes that~~data ~~BioBalance will continue to operate using existing funds, proceeds from~~that ~~the~~ is ~~healthcare~~ clinically ~~operations,~~or ~~proceeds~~statistically ~~from~~useful ~~the~~in ~~sale~~demonstrating ofefficacy, ~~the healthcare operations~~produced ~~and/or~~ encouraging ~~the~~preliminary ~~sale of additional securities~~results. ItThe ~~will~~Company beis ~~necessary~~contemplating ~~for~~various ~~the Company~~options to including ~~secure additional~~ funding incosts ~~order~~relating to ~~begin~~clinical ~~the~~research ~~Phase~~and ~~I/II~~statistical ~~clinical trial,~~analysis ~~which~~ for ~~was~~a ~~approved~~follow byup ~~FDA on March 24, 2006~~study.

Recent Accounting Pronouncements

In ~~February~~December ~~2006~~2007, the ~~Financial~~FASB ~~Accounting~~issued ~~Standards~~SFAS ~~Board~~No. 141 (~~“FASB”~~revised 2007), ~~issued SFAS NO~~"Business Combinations." ~~155,~~SFAS 141(R) ~~Accounting~~broadens ~~for~~the ~~Certain~~guidance ~~Hybrid~~of ~~Financial~~SFAS ~~Instruments-~~141, Anextending ~~Amendment~~its ofapplicability ~~FASB~~to all ~~No.~~transactions ~~133~~ and ~~140.~~other ~~The~~events ~~purpose~~in ofwhich ~~SFAS~~one ~~statement~~entity ~~No.~~obtains ~~155~~control isover ~~to simplify the~~one ~~accounting~~or more ~~for~~other ~~certain~~businesses. ~~hybrid~~It ~~financial~~broadens ~~instruments~~the ~~by permitting~~ fair value measurement and recognition ~~re-measurement~~of assets ~~for~~acquired, ~~any~~liabilities ~~hybrid~~assumed, ~~financial~~and ~~instrument~~interests ~~that~~transferred ~~contains~~as ana ~~embedded~~result ~~derivative~~of business ~~that~~combinations. ~~otherwise~~SFAS ~~would~~141(R) ~~require~~expands ~~bifurcation.~~on ~~SFAS~~required ~~No.~~disclosures ~~155~~to ~~also~~improve ~~eliminates~~ the ~~restriction~~statement onusers' ~~passive~~abilities ~~derivative~~to ~~instruments~~evaluate ~~that~~the anature ~~qualifying~~and financial effects ~~special-purpose~~of business ~~entity may hold~~combinations. SFAS ~~No.~~141(R) ~~155~~ is effective for ~~all~~our ~~financial~~fiscal year beginning ~~instruments~~January ~~acquired~~1, or2009. ~~issued~~The ~~after~~adoption ~~the~~of ~~beginning~~SFAS of141(R) ~~any~~is ~~entity's~~not ~~first~~expected ~~fiscal~~to have a material ~~year~~impact ~~beginning~~on ~~after~~the ~~September~~Company's 15financial position, ~~2006.~~results of operations or cash flows.

5In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51. " SFAS 160 requires that a noncontrolling interest in a subsidiary be reported as equity and the amount of consolidated net income specifically attributable to the noncontrolling interest be identified in the consolidated financial statements. It also calls for consistency in the manner of reporting changes in the parent's ownership interest and requires fair value measurement of any noncontrolling equity investment retained in a deconsolidation. SFAS 160 is effective for our fiscal year beginning January 1, 2009. We have not yet determined the impact of adopting SFAS 160 on the Company's financial position, results of operations or cash flows.

In March 2006, the FASB issued SFAS No. 156, Accounting for Servicing of Financial Assets, an Amendment of SFAS No. 140. SFAS No. 156 requires separate recognition of a servicing asset and a servicing liability each time an entity undertakes and obligation to service a financial asset by entering into a servicing contract. This statement also requires that servicing assets and liabilities be initially recorded at fair value and subsequently adjusted to the fair value at the end of each reporting period. This statement is effective in fiscal years beginning after September 15, 2006. 3

In ~~December 2004~~June, 2006, the FASB issued ~~SFAS~~Interpretation No. 48, Accounting ~~123~~for ~~(revised~~Uncertainty ~~2004),~~in ~~“Share-Based Payment~~Income Taxes,” oran ~~SFAS~~Interpretation of FASB Statement No. 109, ~~123R.~~Accounting ~~SFAS~~for ~~No.~~Income ~~123R~~Taxes (FIN48), to ~~which~~create ~~replaces~~a ~~SFAS~~single ~~No.~~model ~~123~~to ~~and~~address accounting for uncertainty in tax positions. ~~supersedes~~FIN ~~APB~~48 ~~Opinion~~clarifies ~~No.~~the ~~25,~~accounting ~~requires~~for ~~that~~income ~~compensation~~taxes ~~cost~~by ~~relating~~prescribing toa minimum ~~share-based~~recognition ~~payment~~threshold ~~transactions~~a betax ~~recognized~~position is required to meet before being recognized in the financial statements. FIN 48 also provides guidance on derecognition, ~~based~~measurement, onclassification, ~~the~~interest, ~~fair~~and ~~value~~penalties, ofaccounting ~~the~~in ~~equity~~interim periods, ordisclosure ~~liability~~and ~~instruments issued~~transition. OnThe ~~April~~Company adopted FIN 48 as of 14January 1, ~~2005~~2007. Based on our evaluation, ~~the~~we ~~SEC~~have ~~staff~~concluded ~~postponed~~that ~~implementation~~there ofare no ~~SFAS~~significant ~~No.~~uncertain ~~123~~tax ~~(R)~~positions ~~and~~requiring itrecognition in our financial ~~is effective~~statements. Our evaluation was performed for the ~~Company~~tax years which remain subject to examination by major tax jurisdictions as of ~~the~~December ~~beginning~~31, of2007. ~~the~~We ~~first~~may ~~interim~~from time to time be assessed interest or ~~annual~~penalties by major tax jurisdictions, ~~reporting~~although ~~period~~any ~~that~~such ~~begins~~assessments ~~after~~historically ~~December~~have ~~15,~~been ~~2005~~minimal and ~~applies~~ immaterial to our ~~all~~financial ~~awards~~results. In the event we have received an assessment for interest ~~granted,~~and/or ~~modified~~penalties, ~~repurchased~~it orhas ~~cancelled~~been ~~after~~classified in the ~~effective~~financial ~~date~~statements as selling, general and administrative expense. The Company is currently subject to a three ~~adoption~~year statue of ~~this~~limitations ~~statement~~by ~~will~~major ~~increase~~tax ~~reported~~jurisdictions. ~~expenses~~The Company and its subsidiaries file income tax returns in the ~~magnitude~~U.S. federal jurisdiction, New ofYork ~~the~~State, ~~impact~~New isYork ~~still~~City ~~being~~and ~~determined.~~New Jersey.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Generally, the fair market value of fixed rate debt will increase as interest rates fall and decrease as interest rates rise. The Company had no interest rate exposure on fixed rate debt or other market risk at ~~June~~March 3031, ~~2006~~2008.

ITEM 4. CONTROLS AND PROCEDURES

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934 (the "~~Exchange~~ Exchange Act"), the Company's management, with the participation of the Company's Chief Executive Officer ("CEO") and Principal Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report in reaching a reasonable level of assurance that the information required to be disclosed by the Company in the reports that it files with the Securities and Exchange Commission (“SEC”) is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms. Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were not effective with respect to supervision as of the end of the period covered by this report, as we have not had sufficient time to implement the remediation of the weakness as discussed in the form 10-K for the year ended December 31, 2007. The remediation is currently scheduled to be implemented in the third quarter of the current fiscal year.

As required by Exchange Act Rule 13a-15(d), the Company's management, including the Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the Company's internal control over financial reporting to determine whether any changes occurred during the fiscal quarter ended ~~June~~March 3031, ~~2006~~2008 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. Based on that evaluation, other than the changes reported in the Company’'s Annual Report on Form 10-K for the year ended December 31, ~~2005~~2007, which remained in effect during the quarter ended ~~June~~March 3031, ~~2006~~2008, there were no other changes during such quarter.

PART II.

ITEM 1 A. RISK FACTORS

There have been no material changes in the Company’'s risk factors from those disclosed in the Company’'s Annual Report on Form 10-K for the year ended December 31, ~~2005~~2007.

ITEM 6. EXHIBITS ~~AND REPORTS ON FORM 8-K~~

(a)

Exhibits

Exhibit No.	Description	~~Description~~
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	~~Certification of the Chief Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002~~
32.1		Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this ~~report~~Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NEW YORK HEALTH CARE, INC.
August 14, 2006	By:	/s/ Dennis M. O’Donnell
May 19, 2008	By:	/s/ Murry Englard
		Dennis M. O’Donnell President and Chief Executive Officer and Principal Financial Officer
		Name: Murry Englard
		Title: Chief Executive Officer
May 19, 2008	By:	/s/ Stewart W. Robinson
		Name: Stewart W. Robinson
		Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
Exhibit
31.1		Certification of the Chief Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
No.	Description
32.1		Certification of the Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Filing Compare · NEW YORK HEALTH CARE INC